When Klebsiella pneumoniae encounters the acidic environment inside an infected human body, it doesn't simply persist—it transforms, becoming up to 64 times more resistant to the antibiotics designed to kill it. This striking discovery from the Levin Lab at Washington University in St. Louis, published in mBio, reveals a hidden survival mechanism that laboratory tests have consistently missed, and it points to a fundamental flaw in how scientists screen for antibiotic effectiveness.
The problem is deceptively simple: researchers typically test antibiotics in controlled, neutral-pH laboratory settings that bear little resemblance to the acidic conditions present during active infections in the human body. Sarah Beagle, the lead author of the study, captures the urgency of the moment. "We're very rapidly approaching a point where antibiotic resistance is going to be a real problem. We have to work on ways of maximizing what we already have, making our arsenal of drugs more effective," she explains. With antibiotic resistance now a global health threat, understanding how bacteria adapt to their actual environment—not just a petri dish—has become critical.
The researchers focused on K. pneumoniae, one of the world's most antibiotic-resistant pathogens and a major cause of deadly infections. When grown at pH 5, the acidic level found in parts of the human body during infection, the bacterium became dramatically more resistant to beta-lactam antibiotics—the most widely prescribed treatment for bacterial infections. Beta-lactams work by disabling proteins called PBPs that bacteria use to build their cell walls. Without functioning cell walls, bacteria can't divide or survive.
But K. pneumoniae has a secret weapon. The researchers discovered that when conditions turn acidic, the bacterium activates backup copies of these cell wall-building proteins: PBP2PARA, PBP3PARA, and PBP1b. These duplicate genes sit dormant under normal conditions, but spring into action as a protective response to acidic stress. It's a backup team the bacteria brings in when conditions get tough. "K. pneumoniae has a backup set of cell wall-building proteins that come online as the cell enters, in this case, an acidic environment," Beagle explains.
What makes this finding particularly striking is that past antibiotic resistance research relied heavily on E. coli, a common model organism that lacks these duplicate proteins entirely. The discovery forces a reckoning with how scientists have been testing drugs all along. "This sets up a lot of implications for reevaluating and rethinking how we're assessing antibiotic resistance in pathogens," Beagle notes.
To confirm the importance of these proteins, researchers deliberately silenced them—a standard genetic technique. When they did, the bacteria lost much of its antibiotic resistance. "PBP1b and PBP3PARA make the most impact on resistance, so their presence is most critical to the cell at low pH," Beagle confirmed.
The findings suggest a promising path forward. Rather than waiting for entirely new antibiotics—a process that takes years and enormous resources—scientists might develop compounds that work alongside existing drugs to disable these backup proteins under infection-like conditions. "The ultimate goal is to look for compounds or therapeutics that we can use alongside our current antibiotics to kill more effectively under host-like conditions," Beagle says. By designing experiments that actually reflect how infections behave in human bodies, researchers hope to extend the life and effectiveness of the antibiotics we already have.